OXIDIZED LOW-DENSITY LIPOPROTEIN-MEDIATED ACTIVATION OF PHOSPHOLIPASE-D IN SMOOTH-MUSCLE CELLS - A POSSIBLE ROLE IN CELL-PROLIFERATION AND ATHEROGENESIS
V. Natarajan et al., OXIDIZED LOW-DENSITY LIPOPROTEIN-MEDIATED ACTIVATION OF PHOSPHOLIPASE-D IN SMOOTH-MUSCLE CELLS - A POSSIBLE ROLE IN CELL-PROLIFERATION AND ATHEROGENESIS, Journal of lipid research, 36(9), 1995, pp. 2005-2016
Low density lipoproteins (LDL) are risk factors in atherosclerosis and
oxidative modification of LDL to oxidized LDL (OX-LDL) increases its
atherogenicity. Development of atherosclerosis likely involves OX-LDL-
mediated smooth muscle cell (SMC) proliferation. However, the mechanis
m(s) of SMC proliferation by OX-LDL is unknown. We hypothesized that O
X-LDL may mediate SMC proliferation by activation of phospholipase D (
PLD) through the generation of the second-messenger, phosphatidic acid
(PA). To test this hypothesis, activation of PLD by OX-LDL was invest
igated in [H-3]myristic acid- or [P-32]orthophosphate-labeled rabbit f
emoral artery smooth muscle cells (RFASMC) in the presence of 0.5% eth
anol or 0.05% butanol. Phospholipase D activation, as measured by labe
led phosphatidylethanol (PEt) or phosphatidylbutanol (PBt) formation,
was enhanced (3- to 5-fold) by OX-LDL. This activation of PLD was spec
ific for OX-LDL, as native LDL or acetylated LDL had no effect. Furthe
r, OX-LDL-mediated [P-32]PEt formation was dose- and time-dependent. T
o determine the mechanism(s) of OX-LDL-induced PLD activation, the rol
e of protein kinase C (PKC) and Ca2+ was investigated. Pretreatment of
[P-32]orthophosphate-labeled RFASMC with known inhibitors of PKC such
as staurosporine, calphostin-C, or H-7, had no effect on OX-LDL-induc
ed PLD activation. Also, down-regulation of PKC by 12-O-tetradecanoylp
horbol 13-acetate (TPA) (100 nM, 18 h) did not alter the OX-LDL-mediat
ed [P-32]PEt formation. However, pretreatment of RFASMC with genistein
, a putative inhibitor of tyrosine kinases, attenuated the OX-LDL-medi
ated [P-32]PEt formation. In addition, exposure of RFASMC to sodium or
thovanadate, an inhibitor of phosphatases, enhanced the OX-LDL-mediate
d PLD activation. The effects of genistein and vanadate on PLD activat
ion were specific for OX-LDL as these agents did not alter the TPA-ind
uced [P-32]PEt formation. Treatment of quiescent RFASMC with OX-LDL in
creased [H-3]thymidine incorporation into DNA. This enhanced incorpora
tion of [H-3]thymidine into DNA was also mimicked by exogenously added
phosphatidic acid (PA) or lysophosphatidic acid (LPA). These findings
suggest that OX-LDL is a potent activator of the PLD pathway in SMC.
The activation of PLD by OX-LDL generates second-messengers like PA an
d/or LPA which modulate mitogenesis. Thus, these results indicate that
OX-LDL, in atherosclerotic lesions, may enhance SMC proliferation thr
ough the modulation of signal transduction pathways including activati
on of PLD.